Endocrine system

Global Dental Preventive Supplies Market Growth Trajectory & Analytics 2021-2027: Focus on Prevention of Dental Caries to Fuel Demand for Dental Preventive Supplies - ResearchAndMarkets.com

Retrieved on: 
Friday, July 2, 2021
Dental, Health, Endocrine disruptors, Nonsteroidal antiandrogens, Xenoestrogens, Endocrine system, Plasticizers, Selective estrogen receptor modulators, Branches of biology, Drugs, Health effects of Bisphenol A, Bisphenol A, Exposure

Risk of Exposure to BPA: A Cause of Concern

Key Points: 

Risk of Exposure to BPA: A Cause of Concern

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Peptide hormones, Endocrine system, Diabetes, Biology, Recombinant proteins, Anti-diabetic drugs, Pramlintide, Insulin analog, Insulin pump, Amylin, Insulin

So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.

Key Points: 
  • So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.
  • Adocia has developed two products, M1Pram in pen for Multiple Daily Injection, currently in Phase 2, and now BC LisPram for insulin pump delivery.
  • BioChaperone Lispro Pramlintide (BC LisPram) is a fixed combination of two approved hormones analogs, the insulin analog lispro and the amylin analog pramlintide.
  • Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes.

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Peptide hormones, Endocrine system, Diabetes, Biology, Recombinant proteins, Anti-diabetic drugs, Pramlintide, Insulin analog, Insulin pump, Amylin, Insulin

So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.

Key Points: 
  • So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.
  • Adocia has developed two products, M1Pram in pen for Multiple Daily Injection, currently in Phase 2, and now BC LisPram for insulin pump delivery.
  • BioChaperone Lispro Pramlintide (BC LisPram) is a fixed combination of two approved hormones analogs, the insulin analog lispro and the amylin analog pramlintide.
  • Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes.

It Works! Offers Helpful Tips to Manage Stress as the Focus on Mental Health Is on the Rise

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Articles, Self, Personal life, Anxiety, Life skills, Endocrine system, Stress, Sympathetic nervous system, Psychological stress, Coping, Cortisol

In fact, according to the American Institute of Stress, 33% of Americans have reported feeling extreme stress, with 73% sharing they feel it impacts their mental health.

Key Points: 
  • In fact, according to the American Institute of Stress, 33% of Americans have reported feeling extreme stress, with 73% sharing they feel it impacts their mental health.
  • Coping with stress in an effective way is vital for maintaining overall health and well-being.
  • is offering helpful tips to manage stress when it can often feel overwhelming.
  • Maintain good nutrition - When experiencing stress, the central nervous system releases adrenaline and cortisol, which can negatively impact the digestive system.

Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients

Retrieved on: 
Tuesday, June 29, 2021
Children, Biotechnology, Baby, Maternity, Health, Pharmaceutical, Other Science, Research, Genetics, Consumer, Science, Clinical trials, Endocrine system, Medical specialties, Organ systems, Adrenal gland disorders, Glucocorticoids, Corticosteroids, Congenital disorders of glycosylation, PMM2 deficiency, Adrenal insufficiency, Adrenocorticotropic hormone, Cortisol, Adrenal gland, PMM2-CDG (CDG-Ia), GLM101, a Potential Treatment for PMM2-CDG, Glycomine, Inc., PMM2-CDG (CDG-IA), GLM101, A POTENTIAL TREATMENT FOR PMM2-CDG, GLYCOMINE, INC.

These data provide key insights to improve standard of care, as early recognition of adrenal insufficiency and initiation of glucocorticoid replacement therapy and stress dosing could be lifesaving.

Key Points: 
  • These data provide key insights to improve standard of care, as early recognition of adrenal insufficiency and initiation of glucocorticoid replacement therapy and stress dosing could be lifesaving.
  • The authors conclude that morning cortisol and ACTH levels should be evaluated at least annually for all patients with PMM2-CDG.
  • Through an international collaboration, this study was the first to identify that patients with PMM2-CDG are at risk for secondary adrenal insufficiency and to suggest that morning cortisol and ACTH monitoring should become part of standard care in these patients.
  • The natural history study completed enrollment with 139 PMM2-CDG patients at 11 sites around the world (ClinicalTrials.gov Identifier: NCT03173300 ).

Walmart Revolutionizes Insulin Access & Affordability for Patients With Diabetes With the Launch of the First and Only Private Brand Analog Insulin

Retrieved on: 
Tuesday, June 29, 2021
Retail, Health, Diabetes, Other Retail, Discount, Variety, Department Stores, Pharmaceutical, Branches of biology, Peptide hormones, Recombinant proteins, Endocrine system, Hormones, Diabetes, Insulin, Diabetes management

Walmart announced the launch of the first-ever private brand analog insulin, which will revolutionize the access and affordability to diabetes care by offering customers a significant price savings without compromising quality.

Key Points: 
  • Walmart announced the launch of the first-ever private brand analog insulin, which will revolutionize the access and affordability to diabetes care by offering customers a significant price savings without compromising quality.
  • Available exclusively through Walmarts private ReliOn brand, the new offering includes analog insulin vials ($72.88) and FlexPen ($85.88).
  • ReliOn NovoLog is a rapid-acting insulin analog used to control high blood sugar in adults and children with diabetes.
  • Walmart is a destination for affordable diabetes resources, including blood glucose monitors, lancets and other diabetes management essentials in the ReliOn portfolio.

Development of BioVie’s NE3107 Asset Featured by the American Diabetes Association

Retrieved on: 
Tuesday, June 29, 2021
Diabetes, Organ systems, Branches of biology, Endocrine system, Insulin resistance, Insulin, Type 2 diabetes

NE3107, a new drug candidate in development for Alzheimers and Parkinsons Diseases and other conditions, is an ERK inhibitor that selectively inhibits neuroinflammation and insulin resistance.

Key Points: 
  • NE3107, a new drug candidate in development for Alzheimers and Parkinsons Diseases and other conditions, is an ERK inhibitor that selectively inhibits neuroinflammation and insulin resistance.
  • This relationship has been further advanced for Alzheimers disease, which is being referred in the scientific literature as type 3 diabetes, and is being intensively studied by diabetes and neurodegeneration experts.
  • It is now known that up to 81% of Alzheimers subjects have impaired glucose tolerance or type 2 diabetes, said Cuong Do, Chief Executive Officer of BioVie.
  • In preclinical models NE3107 blocks insulin resistance and neuroinflammation at the right time and place, without inhibiting homeostatic activity.

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

Retrieved on: 
Monday, June 28, 2021
Hormones, Branches of biology, Endocrine system, Glands, Parathyroid gland, Osteoporosis, Parathyroid hormone

EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.

Key Points: 
  • EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.
  • Dr. Tripto-Shkolnik will provide context on the results of the study and the benefits of an oral drug to treat osteoporosis.
  • The conference call will take place on Wednesday, June 30, 2021 from 12-1pm EDT and will include a question-and-answer session.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Global Insulin Pump Market Size & Forecast 2021-2025, with Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021
Medical devices, Health, Hormones, Endocrine system, Clinical medicine, Insulin, Pump, Insulin resistance, Diabetes management

The "Global Insulin Pump Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Insulin Pump Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The global insulin pump market has increased significantly during the years 2018-2020 and projections are made that the market would rise in the next four years i.e.
  • This report provides an in-depth analysis of the global insulin pump market by value, by disease indication, by technology, by end use and by region.
  • The global insulin pump market is consolidated with few major market players operating worldwide.

Insulet’s Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 years

Retrieved on: 
Saturday, June 26, 2021
MEN, Research, Consumer, Technology, Medical devices, Teens, Parenting, Science, Children, Women, Other Technology, Health, Diabetes, Hormones, Clinical medicine, Endocrine system, Insulin pump, Insulin

These results support the feasibility of transitioning directly from MDI to automated insulin delivery with Omnipod 5.

Key Points: 
  • These results support the feasibility of transitioning directly from MDI to automated insulin delivery with Omnipod 5.
  • Insulet also presented data related to the Companys non-AID insulin delivery system products, the Omnipod System and Omnipod DASH System, both currently available in the U.S., Canada, and in several international markets.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • Omnipod, Omnipod DASH, and Omnipod 5 are registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions.